The described clinical case supports the hypothesis that a very small population of tumor-initiating cells, including CD117-positive cells, can survive during the treatment and give rise to an aggressive recurrent tumor therapy resistant phenotype (which led to the death of the patient). This evidence concerns the gene KIT and neoplasm.